BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 29715294)

  • 1. Correction: Analysis of epidemiological association patterns of serum thyrotropin by combining random forests and Bayesian networks.
    Becker AK; Ittermann T; Dörr M; Felix SB; Nauck M; Teumer A; Völker U; Völzke H; Kaderali L; Nath N
    PLoS One; 2023; 18(11):e0294489. PubMed ID: 37948441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction: A new generalized family of distributions based on combining Marshal-Olkin transformation with T-X family.
    Klakattawi H; Alsulami D; Elaal MA; Dey S; Baharith L
    PLoS One; 2023; 18(10):e0293100. PubMed ID: 37824547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction: Synthesis and preclinical application of a Prussian blue-based dual fluorescent and magnetic contrast agent (CA).
    Hegedűs N; Forgách L; Kiss B; Varga Z; Jezsó B; Horváth I; Kovács N; Hajdrik P; Padmanabhan P; Gulyás B; Szigeti K; Máthé D
    PLoS One; 2023; 18(11):e0295460. PubMed ID: 38033129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction: Tacrolimus (FK506) Prevents Early Stages of Ethanol Induced Hepatic Fibrosis by Targeting LARP6 Dependent Mechanism of Collagen Synthesis.
    Manojlovic Z; Blackmon J; Stefanovic B
    PLoS One; 2024; 19(6):e0306020. PubMed ID: 38900747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction: Impulsive fractional order integrodifferential equation via fractional operators.
    PLOS ONE Staff
    PLoS One; 2024; 19(3):e0300611. PubMed ID: 38466722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease.
    Feldman DL
    Hypertens Res; 2010 Apr; 33(4):279-87. PubMed ID: 20203685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats.
    Eren Z; Günal MY; Bakir EA; Coban J; Çağlayan B; Ekimci N; Ethemoglu S; Albayrak O; Akdeniz T; Demirel GY; Kiliç E; Kantarci G
    Kidney Blood Press Res; 2014; 39(6):581-90. PubMed ID: 25532067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synergistic effect of mizoribine and a direct renin inhibitor, aliskiren, on unilateral ureteral obstruction induced renal fibrosis in rats.
    Sakuraya K; Endo A; Someya T; Hirano D; Murano Y; Fujinaga S; Ohtomo Y; Shimizu T
    J Urol; 2014 Apr; 191(4):1139-46. PubMed ID: 24140549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
    Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK
    Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria.
    Riera M; Anguiano L; Clotet S; Roca-Ho H; Rebull M; Pascual J; Soler MJ
    Am J Physiol Renal Physiol; 2016 Mar; 310(6):F534-46. PubMed ID: 26697977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin.
    Chung S; Kim S; Kim M; Koh ES; Shin SJ; Park CW; Chang YS; Kim HS
    PLoS One; 2017; 12(7):e0181757. PubMed ID: 28753620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction: Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin.
    Chung S; Kim S; Kim M; Koh ES; Shin SJ; Park CW; Chang YS; Kim HS
    PLoS One; 2018; 13(5):e0196885. PubMed ID: 29715294
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.